Mechanisms of Action of Metformin in Type 2 Diabetes and Associated Complications: An Overview
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes is a major health problem associated with excess mortality and morbidity. Vascular complications are one of the most serious consequences of this disorder. Moreover, type 2 diabetes is also a risk factor for cerebral complications, including cognitive impairment and dementia. However, it has been shown that tight glycemic control contributes to reduce the incidence of diabetes-associated complications. Metformin is a potent antihyperglycemic agent widely used in the management of type 2 diabetes whose main actions are the suppression of gluconeogenesis and the improvement of glucose uptake and insulin sensitivity. This review is mainly devoted to describe the mechanisms of action underlying the antidiabetic effects of metformin. Furthermore, we will present evidence for the protective effects of metformin against diabetes-associated complications mainly cerebral and vascular complications. Finally, we will describe the few known side effects associated to this antidiabetic agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001
Mokdad, A. H., Ford, E. S., Bowman, B. A., Dietz, W. H., Vinicor, F., Bales, V. S., & Marks, J. S. (2003) · JAMA · doi:10.1001/jama.289.1.76 · Cited by 5,866 · cited 1×
“It has been postulated that this disorder is associated with an increased prevalence of vascular risk factors, including hyperglycemia, hypertension and dyslipidemia [90-92].”
BackgroundRisk of dementia in diabetes mellitus: a systematic review
Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C., & Scheltens, P. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70284-2 · Cited by 2,187
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157 · cited 1×
“Despite the metformin’s mechanisms of action in hepatocytes remain uncertain, the primary site of action of this drug appears to be mitochondria, since metformin inhibits mitochondrial respiratory chain particularly at the complex I level, impairing mitochondrial function and, consequently, cell function [47-49].”
BackgroundTurner, R. C., Millns, H., Neil, H. A. W., Stratton, I. M., Manley, S. E., Matthews, D. R., & Holman, R. R. (1998) · BMJ · doi:10.1136/bmj.316.7134.823 · Cited by 2,014
Roles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956 · cited 1×
“So, the major effect of the thiazolidinediones is the improvement of insulin sensitivity [28,29].”
BackgroundThe Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950 · cited 1×
“Recent studies demonstrated that serine-threonine kinase 11 (STK11/LKB1), which phosphorylates AMPK, is also a target of metformin [75,76].”
BackgroundRole of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM
Boden, G. (1997) · Diabetes · doi:10.2337/diab.46.1.3 · Cited by 1,728
LKB1 is the upstream kinase in the AMP-activated protein kinase cascade
Woods, A., Johnstone, S. R., Dickerson, K., Leiper, F. C., Fryer, L. G. D., Neumann, D., Schlattner, U., Wallimann, T., Carlson, M., & Carling, D. (2003) · Current Biology · doi:10.1016/j.cub.2003.10.031 · Cited by 1,650
Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study
Garcia, M. J., McNamara, P. M., Gordon, T., & Kannell, W. B. (1974) · Diabetes · doi:10.2337/diab.23.2.105 · Cited by 1,608
McGarry, J. D. (2002) · Diabetes · doi:10.2337/diabetes.51.1.7 · Cited by 1,435
El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399 · cited 1×
“Despite the metformin’s mechanisms of action in hepatocytes remain uncertain, the primary site of action of this drug appears to be mitochondria, since metformin inhibits mitochondrial respiratory chain particularly at the complex I level, impairing mitochondrial function and, consequently, cell function [47-49].”
BackgroundPrognostic Value of Coronary Vascular Endothelial Dysfunction
Halcox, J. P. J., Schenke, W. H., Zalos, G., Mincemoyer, R., Prasad, A., Waclawiw, M. A., Nour, K. R. A., & Quyyumi, A. A. (2002) · Circulation · doi:10.1161/01.cir.0000025404.78001.d8 · Cited by 1,385 · cited 1×
“Therefore, endothelial dysfunction, a hallmark of type 2 diabetes, is intimately involved in the onset of diabetic vascular complications [95,96].”
BackgroundEfficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368 · cited 1×
“Furthermore, it has been reported that metformin treatment counteracts insulin resistance, reduces hyperinsulinemia, reduces body mass index and improves lipid profile, especially by reducing triglycerides and low density lipoproteins (LDL)-cholesterol levels and increasing high density lipoproteins (HDL)-cholesterol…”
BackgroundMetformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291 · cited 1×
“It has also been shown that in women with gestational diabetes mellitus, metformin (alone or with supplemental insulin) is not associated with increased perinatal complications as compared with insulin [39].”
BackgroundRidker, P. M., Hennekens, C. H., Roitman-Johnson, B., Stampfer, M. J., & Allen, J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)09032-6 · Cited by 1,229 · cited 1×
“The increased levels of soluble forms of these molecules have been associated with increased risk of coronary events [142-144].”
BackgroundPharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148 · cited 1×
“One drug widely used in the treatment of type 2 diabetes is metformin, a potent antihyperglycemic drug that suppresses hepatic gluconeogenesis [18,19], increases muscular glucose uptake [20,21] and ameliorates insulin sensitivity [22].”
BackgroundKirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084
Festa, A., D’Agostino, R., Tracy, R. P., & Haffner, S. M. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1131 · Cited by 1,057
Mechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052 · cited 1×
“Indeed, several studies demonstrated that metformin reduces glucose production mainly due to an inhibitory effect on gluconeogenesis [41-45].”
BackgroundMusi, N., Hirshman, M. F., Nygren, J., Svanfeldt, M., Bavenholm, P., Rooyackers, O., Zhou, G., Williamson, J. M., Ljunqvist, O., Efendic, S., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2074 · Cited by 806 · cited 1×
“Although the molecular mechanism underlying metformin action remains unclear, it has been suggested that this drug activates AMPK, a major regulator of cell and body energy homeostasis, by increasing its phosphorylation state but without any changes in AMP/ ATP ratio [72-74] (Fig.”
BackgroundPoitout, V., & Robertson, R. P. (2002) · Endocrinology · doi:10.1210/endo.143.2.8623 · Cited by 743
Biomarkers of Endothelial Dysfunction and Risk of Type 2 Diabetes Mellitus
Meigs, J. B. (2004) · JAMA · doi:10.1001/jama.291.16.1978 · Cited by 643 · cited 1×
“These elevated levels of PAI-1 result in impaired fibrinolysis and increased risk of thrombosis [114-123].”
BackgroundType 2 diabetes mellitus, cognitive impairment and dementia
Stewart, R., & Liolitsa, D. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00027.x · Cited by 562
Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus
Mather, K. J., Verma, S., & Anderson, T. J. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01129-9 · Cited by 513 · cited 1×
“Furthermore, in vitro and in vivo studies demonstrated that this antihyperglycemic drug improves vascular reactivity to the endothelium-dependent vasodilator acetylcholine in insulin resistant rats [130,131].”
BackgroundAgeing and diabetes: implications for brain function
Biessels, G. J., van der Heide, L. P., Kamal, A., Bleys, R. L. A. W., & Gispen, W. H. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01486-3 · Cited by 458
Ferrannini, E. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.4.0336 · Cited by 451
Diabetes mellitus as a prothrombotic condition
Grant, P. J. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01824.x · Cited by 443 · cited 1×
“These elevated levels of PAI-1 result in impaired fibrinolysis and increased risk of thrombosis [114-123].”
BackgroundIncreased intake of calcium reverses vitamin B12 malabsorption induced by metformin
Bauman, W. A., Shaw, S., Jayatilleke, E., Spungen, A. M., & Herbert, V (2000) · Diabetes Care · doi:10.2337/diacare.23.9.1227 · Cited by 412
Risk Factors of Vitamin B12 Deficiency in Patients Receiving Metformin
Ting, R. Z.-W. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.18.1975 · Cited by 333 · cited 1×
“This antidiabetic drug has also been implicated with increased homocysteine levels [173] and vitamin B12 deficiency [174-176].”
BackgroundAllen, K. V., Frier, B. M., & Strachan, M. W. J. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.054 · Cited by 319
Detaille, D., Guigas, B., Chauvin, C., Batandier, C., Fontaine, E., Wiernsperger, N., & Leverve, X. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2179 · Cited by 263
Meta-analysis: metformin treatment in persons at risk for diabetes mellitus
Salpeter, S. R., Buckley, N. S., Kahn, J. A., & Salpeter, E. E. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.09.016 · Cited by 248
Metformin Decreases Intracellular Production of Reactive Oxygen Species in Aortic Endothelial Cells
Ouslimani, N., Peynet, J., Bonnefont-Rousselot, D., Thérond, P., Legrand, A., & Beaudeux, J.-L. (2005) · Metabolism · doi:10.1016/j.metabol.2005.01.029 · Cited by 204 · cited 1×
“In vitro studies using bovine aortic endothelial cells (BAEC) also shown that metformin decreases the intracellular production of ROS [147,148] through the inhibition of PKC [148].”
BackgroundPatanè, G., Piro, S., Rabuazzo, A. M., Anello, M., Vigneri, R., & Purrello, F. (2000) · Diabetes · doi:10.2337/diabetes.49.5.735 · Cited by 169 · cited 1×
“So, reduction in the concentration of plasma FFA can contribute to the improvement in insulin action and may also help to correct impaired insulin secretion by -cells [69].”
BackgroundJohnson, J. A., Simpson, S. H., Toth, E. L., & Majumdar, S. R. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01448.x · Cited by 161
Caballero, A. E., Delgado, A., Aguilar-Salinas, C. A., Herrera, A. N., Castillo, J. L., Cabrera, T., Gomez-Perez, F. J., & Rull, J. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0019 · Cited by 151 · cited 1×
“Metformin also reduces the levels of soluble intercellular cell-adhesion molecules (ICAM-1) and soluble vascular cell-adhesion molecules (VCAM-1) in subjects with impaired glucose tolerance [140].”
BackgroundCharles, M. A., Morange, P., Eschwège, E., André, P., Vague, P., & Juhan-Vague, I. (1998) · Diabetes Care · doi:10.2337/diacare.21.11.1967 · Cited by 120 · cited 1×
“Furthermore, this drug affects the coagulation system inducing a reduction in fibrinogen [126] and von Willebrand factor (vWF) levels [127].”
BackgroundRole of Metformin for Weight Management in Patients Without Type 2 Diabetes
Desilets, A. R., Dhakal-Karki, S., & Dunican, K. C. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1k656 · Cited by 111
Rösen, P., & Wiernsperger, N. F. (2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.623 · Cited by 102 · cited 1×
“Further, an in vivo study performed in Goto-Kakizaki (GK) rats, a model of type 2 diabetes, demonstrated that metformin delays the manifestation of diabetes and vascular dysfunction by the reduction of mitochondrial oxidative stress [139].”
BackgroundCardiovascular Risk Factors Associated with Insulin Resistance: Effects of Oral Antidiabetic Agents
Granberry, M. C., & Fonseca, V. A. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505030-00006 · Cited by 38 · cited 1×
“It has been described that metformin improves vascular functions and dramatically reduces the incidence of vascular complications [97,98].”
Background
Cited by
Metformin improves healthspan and lifespan in mice
Martin-Montalvo, A., Mercken, E. M., Mitchell, S. J., Palacios, H. H., Mote, P. L., Scheibye-Knudsen, M., Gomes, A. P., Ward, T. M., Minor, R. K., Blouin, M.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3192 · Cited by 1,445
Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
M. de la Monte, S. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015037 · Cited by 448
Insulin in Central Nervous System: More than Just a Peripheral Hormone
Duarte, A. I., Moreira, P. I., & Oliveira, C. R. (2012) · Journal of Aging Research · doi:10.1155/2012/384017 · Cited by 322
Self-citationde la Monte, S. M. (2012) · Drugs · doi:10.2165/11597760-000000000-00000 · Cited by 265
“Metformin protects against neurological complications of T2DM, including cognitive impairment and cerebral vascular disease.([160]) Although metformin treatment may increase both intra- and extracellular AbPPAb due to increased expression of b-secretase 1 (BACE1), when administered with insulin, metformin provides sig…”
BackgroundPintana, H., Apaijai, N., Pratchayasakul, W., Chattipakorn, N., & Chattipakorn, S. C. (2012) · Life Sciences · doi:10.1016/j.lfs.2012.08.017 · Cited by 236
Metadata
- Authors
- Correia, S., Carvalho, C., Santos, M., Seica, R., Oliveira, C., & Moreira, P.
- Venue
- Mini-Reviews in Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2008-11-01
- Volume
- 8
- Issue
- 13
- Pages
- 1343-1354
- ISSN
- 1389-5575 (ISSN-L)
- OpenAlex
- W2145540652
- Cited by
- 96
- References
- 41
- FWCI
- 1.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.